Search hospitals > South Carolina > Greer
Prisma Health Cancer Institute - Greer
Claim this profileGreer, South Carolina 29650
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Lung Cancer
Conducts research for Cancer
249 reported clinical trials
8 medical researchers
Summary
Prisma Health Cancer Institute - Greer is a medical facility located in Greer, South Carolina. This center is recognized for care of Skin Cancer, Breast Cancer, Breast cancer, Lung Cancer, Cancer and other specialties. Prisma Health Cancer Institute - Greer is involved with conducting 249 clinical trials across 434 conditions. There are 8 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Ki Chung, MDPrisma Health Cancer Institute - Eastside6 years of reported clinical research
Expert in Skin Cancer
Expert in Uterine Tumors
97 reported clinical trials
199 drugs studied
Aniket SahaBI-LO Charities Children's Cancer Center7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
59 reported clinical trials
120 drugs studied
Jeffrey K. GiguerePrisma Health Cancer Institute - Faris8 years of reported clinical research
Studies Cancer
Studies Breast Cancer
26 reported clinical trials
64 drugs studied
Suzanne R. FanningPrisma Health Cancer Institute - Eastside2 years of reported clinical research
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Lymphoma
12 reported clinical trials
35 drugs studied
Clinical Trials running at Prisma Health Cancer Institute - Greer
Breast Cancer
Breast cancer
Skin Cancer
Cancer
Lung Cancer
Acute Myeloid Leukemia
Bladder Cancer
Uterine Tumors
Lymphoma
Testicular cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Prisma Health Cancer Institute - Greer?
Prisma Health Cancer Institute - Greer is a medical facility located in Greer, South Carolina. This center is recognized for care of Skin Cancer, Breast Cancer, Breast cancer, Lung Cancer, Cancer and other specialties. Prisma Health Cancer Institute - Greer is involved with conducting 249 clinical trials across 434 conditions. There are 8 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.